All‐cause mortality (at end of
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (at end of compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 90 days)
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (within 90 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 30 days)
Albumin and fresh frozen plasma showed no clear difference in all‐cause mortality (within 30 days) compared with crystalloid (moderate certainty).
1 finding from 1 review
Transfusion of blood products
It is very uncertain whether albumin and fresh frozen plasma changes transfusion of blood products compared with crystalloid (very low certainty).
1 finding from 1 review
Renal replacement therapy
Albumin and fresh frozen plasma showed no clear difference in renal replacement therapy compared with crystalloid (low certainty).
1 finding from 1 review
Adverse events
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Incidence of hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
It is very uncertain whether summary of findings: Fresh frozen plasma changes incidence of hepatic veno‐occlusive disease ( compared with no treatment (very low certainty).
1 finding from 1 review
Overall survival · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality attributable to hepatic veno‐occlusive disease ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Frequency of adverse events ( · Patients undergoing stem cell transplant with malignant and non‐malignant diseases
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Total oocytes ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Total dose of gonadotropins (IU) ‐ Normoresponders ‐ Donor oocytes ‐ Early ophase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists · assisted reproduction technology cycles
1 finding from 1 review
Moderate or severe OHSS ‐ Normoresponders ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer (MPA 10 mg/day versus GnRH antagonists) · assisted reproduction technology cycles
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (MPA 10 mg versus GnRH antagonists) ‐ Donor oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders (micronised progesterone 200 mg versus GnRH antagonists) ‐ Own oocytes ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation sensitivity analysis ‐ Normoresponders… compared with gnRH antagonists; GRADE not reported.
1 finding from 1 review
Oocyte pick‐up cancellation · assisted reproduction technology cycles
Summary of findings table ‐ Progestogens showed no clear difference in oocyte pick‐up cancellation ‐ Normoresponders (MPA 10 mg versus GnRH… compared with gnRH antagonists; GRADE not reported.
2 findings from 1 review
Premature LH surge ‐ Donor oocytes ‐ Normoresponders ‐ Early phase stimulation protocol ‐ Fresh embryo transfer · assisted reproduction technology cycles
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Live birth rate per fresh transfer · Patients with subfertility
Blastocyst‐stage may leads to higher live birth rate per fresh transfer compared with cleavage‐stage embryo transfer (low certainty).
1 finding from 1 review